Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews · Neuromuscular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 14.3%Very low 4 · 57.1%Low 1 · 14.3%Moderate 1 · 14.3%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Cerebrospinal fluid filtration vs plasma exchange · Participants with 1 or more serious adverse events
  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  RR 0.13 [0.01, 2.25]
  1 study · 37 participants
  Very low
Direct match · question page
- Brain‐derived neurotrophic factor vs placebo · Participants with 1 or more serious adverse events
  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  RR 1 [0.28, 3.54]
  1 study · 10 participants
  Very low
Direct match · question page
- Eplerenone (25 mg daily) vs placebo · Adverse events
  Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
  RR 0.37 [0.02, 8.48]
  1 study · 42 participants
  Very low
Direct match · question page
- Corticosteroids vs placebo · Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment
  Corticosteroids for treating nerve damage in leprosy 2016 · Cochrane Headline outcomes only
  RR 0.83 [0.05, 12.77]
  1 study · 75 participants
  Moderate
Direct match · question page
- Tripterygium polyglycoside vs corticosteroids · Participants with 1 or more serious adverse events
  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 43 participants
  GRADE not reported

Brain‐derived neurotrophic factor vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1 [0.28, 3.54]
1 study · 10 participants
Very low

Cerebrospinal fluid filtration vs plasma exchange

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 0.13 [0.01, 2.25]
1 study · 37 participants
Very low

Tripterygium polyglycoside vs corticosteroids

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
GRADE not reported

Eculizumab vs placebo

Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 1.9 [0.34, 10.5]
2 studies · 41 participants
Low

Interferon beta‐1a vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for… 2020 · Cochrane Headline outcomes only
RR 0.92 [0.23, 3.72]
1 study · 19 participants
Very low

Corticosteroids vs placebo

Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy

Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids for treating nerve damage in leprosy 2016 · Cochrane Headline outcomes only
RR 0.83 [0.05, 12.77]
1 study · 75 participants
Moderate

Eplerenone (25 mg daily) vs placebo

Adverse events · boys with DMD and left ventricular ejection fraction 45% or more

It is very uncertain whether eplerenone (25 mg daily) changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked… 2018 · Cochrane Headline outcomes only
RR 0.37 [0.02, 8.48]
1 study · 42 participants
Very low